Cargando…
High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction
SIMPLE SUMMARY: Afatinib is used to treat non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation as a second-generation EGFR-tyrosine kinase inhibitor (TKI). We examined the relationship between the trough plasma concentrations of afatinib and adverse effects,...
Autores principales: | Takahashi, Takayuki, Terazono, Hideyuki, Suetsugu, Takayuki, Sugawara, Hideki, Arima, Junko, Nitta, Mina, Tanabe, Toru, Okutsu, Kayu, Ikeda, Ryuji, Mizuno, Keiko, Inoue, Hiromasa, Takeda, Yasuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305619/ https://www.ncbi.nlm.nih.gov/pubmed/34298637 http://dx.doi.org/10.3390/cancers13143425 |
Ejemplares similares
-
Successful Treatment with Osimertinib Based on Therapeutic Drug Monitoring in a Hemodialysis Patient with Non-Small Cell Lung Cancer: A Case Report
por: Tabata, Keisuke, et al.
Publicado: (2023) -
MicroRNA signature of small‐cell lung cancer after treatment failure: impact on oncogenic targets by miR‐30a‐3p control
por: Tanigawa, Kengo, et al.
Publicado: (2022) -
Regulation of KIF2A by Antitumor miR-451a Inhibits Cancer Cell Aggressiveness Features in Lung Squamous Cell Carcinoma
por: Uchida, Akifumi, et al.
Publicado: (2019) -
Involvement of dual‐strand of the miR‐144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma
por: Uchida, Akifumi, et al.
Publicado: (2018) -
FAM64A: A Novel Oncogenic Target of Lung Adenocarcinoma Regulated by Both Strands of miR-99a (miR-99a-5p and miR-99a-3p)
por: Mizuno, Keiko, et al.
Publicado: (2020)